Your browser doesn't support javascript.
loading
Cone-Beam-CT Guided Adaptive Radiotherapy for Locally Advanced Non-small Cell Lung Cancer Enables Quality Assurance and Superior Sparing of Healthy Lung.
Hoegen, Philipp; Lang, Clemens; Akbaba, Sati; Häring, Peter; Splinter, Mona; Miltner, Annette; Bachmann, Marion; Stahl-Arnsberger, Christiane; Brechter, Thomas; El Shafie, Rami A; Weykamp, Fabian; König, Laila; Debus, Jürgen; Hörner-Rieber, Juliane.
Afiliação
  • Hoegen P; Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.
  • Lang C; Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.
  • Akbaba S; National Center for Tumor Diseases (NCT), Heidelberg, Germany.
  • Häring P; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Splinter M; Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.
  • Miltner A; Medical Physics in Radiotherapy, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Bachmann M; Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.
  • Stahl-Arnsberger C; Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.
  • Brechter T; National Center for Tumor Diseases (NCT), Heidelberg, Germany.
  • El Shafie RA; Department of Radiation Oncology, Mainz University Hospital, Mainz, Germany.
  • Weykamp F; Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.
  • König L; Medical Physics in Radiotherapy, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Debus J; Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.
  • Hörner-Rieber J; Medical Physics in Radiotherapy, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Front Oncol ; 10: 564857, 2020.
Article em En | MEDLINE | ID: mdl-33363005
ABSTRACT

PURPOSE:

To evaluate the potential of cone-beam-CT (CB-CT) guided adaptive radiotherapy (ART) for locally advanced non-small cell lung cancer (NSCLC) for sparing of surrounding organs-at-risk (OAR). MATERIALS AND

METHODS:

In 10 patients with locally advanced NSCLC, daily CB-CT imaging was acquired during radio- (n = 4) or radiochemotherapy (n = 6) for simulation of ART. Patients were treated with conventionally fractionated intensity-modulated radiotherapy (IMRT) with total doses of 60-66 Gy (pPlan) (311 fraction CB-CTs). OAR were segmented on every daily CB-CT and the tumor volumes were modified weekly depending on tumor changes. Doses actually delivered were recalculated on daily images (dPlan), and voxel-wise dose accumulation was performed using a deformable registration algorithm. For simulation of ART, treatment plans were adapted using the new contours and re-optimized weekly (aPlan).

RESULTS:

CB-CT showed continuous tumor regression of 1.1 ± 0.4% per day, leading to a residual gross tumor volume (GTV) of 65.3 ± 13.4% after 6 weeks of radiotherapy (p = 0.005). Corresponding PTVs decreased to 83.7 ± 7.8% (p = 0.005). In the actually delivered plans (dPlan), both conformity (p = 0.005) and homogeneity (p = 0.059) indices were impaired compared to the initial plans (pPlan). This resulted in higher actual lung doses than planned V20Gy was 34.6 ± 6.8% instead of 32.8 ± 4.9% (p = 0.066), mean lung dose was 19.0 ± 3.1 Gy instead of 17.9 ± 2.5 Gy (p = 0.013). The generalized equivalent uniform dose (gEUD) of the lung was 18.9 ± 3.1 Gy instead of 17.8 ± 2.5 Gy (p = 0.013), leading to an increased lung normal tissue complication probability (NTCP) of 15.2 ± 13.9% instead of 9.6 ± 7.3% (p = 0.017). Weekly plan adaptation enabled decreased lung V20Gy of 31.6 ± 6.2% (-3.0%, p = 0.007), decreased mean lung dose of 17.7 ± 2.9 Gy (-1.3 Gy, p = 0.005), and decreased lung gEUD of 17.6 ± 2.9 Gy (-1.3 Gy, p = 0.005). Thus, resulting lung NTCP was reduced to 10.0 ± 9.5% (-5.2%, p = 0.005). Target volume coverage represented by conformity and homogeneity indices could be improved by weekly plan adaptation (CI p = 0.007, HI p = 0.114) and reached levels of the initial plan (CI p = 0.721, HI p = 0.333).

CONCLUSION:

IGRT with CB-CT detects continuous GTV and PTV changes. CB-CT-guided ART for locally advanced NSCLC is feasible and enables superior sparing of healthy lung at high levels of plan conformity.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Front Oncol Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Front Oncol Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Alemanha